Literature DB >> 19297381

Drug discovery in psychiatric illness: mining for gold.

Greg I Elmer1, Neri Kafkafi.   

Abstract

The discovery of truly efficacious treatments that lead to full recovery is a daunting task in psychiatric illness. A systems-based orientation to in vivo pharmacology has been suggested as a way to transform psychiatric drug discovery and development. A critical catalyst in the success of recent systems biology efforts has been the incorporation of data mining strategies. Our approach to the drug discovery problem has been to utilize the whole animal to provide a systems response that is subsequently mined for predictive attributes with known psychopharmacological value. Our in vivo data mining approach, termed Pattern Array, establishes a framework for screening novel chemical entities based upon a response that represents the net pharmacological effect on the system of interest, namely the central nervous system (CNS). Large scale screening of small molecules by non-conventional approaches such as this at a systems level may improve the identification of novel chemical entities with psychiatric utility. This type of approach will compliment the more labor-intensive models based upon construct validity. It will take the collective effort of many disciplines and numerous strategies in close association with clinical colleagues to address quality of life issues and breakthrough treatment barriers in psychiatric illness.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19297381      PMCID: PMC2659322          DOI: 10.1093/schbul/sbn194

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  51 in total

Review 1.  The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?

Authors:  M L Wadenberg; P B Hicks
Journal:  Neurosci Biobehav Rev       Date:  1999       Impact factor: 8.989

2.  Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

Authors:  A K Malhotra; D A Pinals; C M Adler; I Elman; A Clifton; D Pickar; A Breier
Journal:  Neuropsychopharmacology       Date:  1997-09       Impact factor: 7.853

3.  Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice.

Authors:  I Lucki; A Dalvi; A J Mayorga
Journal:  Psychopharmacology (Berl)       Date:  2001-05       Impact factor: 4.530

4.  SEE locomotor behavior test discriminates C57BL/6J and DBA/2J mouse inbred strains across laboratories and protocol conditions.

Authors:  Neri Kafkafi; Dina Lipkind; Yoav Benjamini; Cheryl L Mayo; Gregory I Elmer; Ilan Golani
Journal:  Behav Neurosci       Date:  2003-06       Impact factor: 1.912

5.  Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro.

Authors:  Erik C Gunther; David J Stone; Robert W Gerwien; Patricia Bento; Melvyn P Heyes
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

Review 6.  Dopamine, learning and motivation.

Authors:  Roy A Wise
Journal:  Nat Rev Neurosci       Date:  2004-06       Impact factor: 34.870

Review 7.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia.

Authors:  Bryan L Roth; Douglas J Sheffler; Wesley K Kroeze
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

8.  Effects of ketamine in normal and schizophrenic volunteers.

Authors:  A C Lahti; M A Weiler; B A Tamara Michaelidis; A Parwani; C A Tamminga
Journal:  Neuropsychopharmacology       Date:  2001-10       Impact factor: 7.853

9.  Darting behavior: a quantitative movement pattern designed for discrimination and replicability in mouse locomotor behavior.

Authors:  Neri Kafkafi; Michal Pagis; Dina Lipkind; Cheryl L Mayo; Yoav Bemjamini; Ilan Golani; Gregory I Elmer
Journal:  Behav Brain Res       Date:  2003-06-16       Impact factor: 3.332

10.  Systematic discovery of multicomponent therapeutics.

Authors:  Alexis A Borisy; Peter J Elliott; Nicole W Hurst; Margaret S Lee; Joseph Lehar; E Roydon Price; George Serbedzija; Grant R Zimmermann; Michael A Foley; Brent R Stockwell; Curtis T Keith
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.